1 Min Read
Oct 11 (Reuters) - 3SBio Inc
* Recombinant humanized anti-VEGF monoclonal antibody for injection (601a) approved by China FDA for clinical trials Source text for Eikon: Further company coverage:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2018 Reuters. All Rights Reserved.